Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-707 in advanced gynecologic cancer
NCT06522828Phase 2Recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tivunatamig in endometrial cancer (EC), ovarian cancer, sponsored by 3S Guojian Pharmaceutical. Started Oct 2024; status: recruiting.
02
Drugs
tivunatamig
03
Conditions
endometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on NCT06522828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06522828.